These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 14743370)
1. Adverse effects of dopamine potentiation by long-term treatment with selegiline. Hollán S; Vécsei L; Magyar K Mov Disord; 2004 Jan; 19(1):107-9. PubMed ID: 14743370 [TBL] [Abstract][Full Text] [Related]
2. Selegiline in Parkinson's disease. Calne DB BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790 [No Abstract] [Full Text] [Related]
3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
4. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Youdim MB; Riederer PF Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584 [No Abstract] [Full Text] [Related]
5. Transdermal selegiline (Emsam). Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292 [No Abstract] [Full Text] [Related]
6. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
7. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]. Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842 [TBL] [Abstract][Full Text] [Related]
10. Rasagiline as a therapy for Parkinson's disease (PD). Hermanowicz N Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520 [No Abstract] [Full Text] [Related]
11. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
12. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Olanow CW; Mytilineou C; Tatton W Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720 [No Abstract] [Full Text] [Related]
13. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721 [TBL] [Abstract][Full Text] [Related]
14. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
16. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Rose LM; Ohlinger MJ; Mauro VF Ann Pharmacother; 2000 Sep; 34(9):1020-4. PubMed ID: 10981248 [TBL] [Abstract][Full Text] [Related]
17. DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074 [TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. Pálfi M; Szökó E; Kálmán M Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880 [TBL] [Abstract][Full Text] [Related]
20. The fabulous neuroprotection of selegiline: memoir and prospectus. Landau WM J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135 [No Abstract] [Full Text] [Related] [Next] [New Search]